Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Stock analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Agios Pharmaceuticals in a research report issued to clients and investors on Thursday, March 6th. Zacks Research analyst A. Chakraborty forecasts that the biopharmaceutical company will post earnings per share of ($3.85) for the year. The consensus estimate for Agios Pharmaceuticals' current full-year earnings is ($6.85) per share.
A number of other brokerages also recently issued reports on AGIO. HC Wainwright assumed coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 price target for the company. Cantor Fitzgerald restated an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. StockNews.com lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, February 14th. Scotiabank boosted their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research report on Monday, December 9th. Finally, Royal Bank of Canada lifted their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $56.57.
Get Our Latest Research Report on Agios Pharmaceuticals
Agios Pharmaceuticals Price Performance
Shares of Agios Pharmaceuticals stock traded up $0.14 during trading on Friday, hitting $32.13. 839,700 shares of the stock were exchanged, compared to its average volume of 681,789. The firm's 50-day moving average price is $33.78 and its 200 day moving average price is $42.18. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of 2.83 and a beta of 0.90. Agios Pharmaceuticals has a 12-month low of $27.14 and a 12-month high of $62.58.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%.
Insider Buying and Selling at Agios Pharmaceuticals
In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.93% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Agios Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in Agios Pharmaceuticals in the 4th quarter valued at $39,000. Frazier Life Sciences Management L.P. boosted its holdings in shares of Agios Pharmaceuticals by 2.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company's stock valued at $35,152,000 after acquiring an additional 25,600 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Agios Pharmaceuticals by 8.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 122,835 shares of the biopharmaceutical company's stock worth $4,036,000 after purchasing an additional 9,606 shares during the period. Voloridge Investment Management LLC increased its position in Agios Pharmaceuticals by 2.1% during the 4th quarter. Voloridge Investment Management LLC now owns 200,481 shares of the biopharmaceutical company's stock worth $6,588,000 after purchasing an additional 4,082 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $5,337,000.
About Agios Pharmaceuticals
(
Get Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
See Also
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
